The identification of maslinic acid as a potential multi-target drug against the intra-erythrocytic cycle of Plasmodium may be highly significant for the treatment of malaria, because most antimalarials target only a single process of the parasite infective cycle, which favours the appearance of resistant mutants (Moneriz et al. 2011 ).
1
—
—